semaglutide compounding fda enforcement today issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Feds warn telehealth companies about

Why the receptor difference matters for alternating When you alternate between semaglutide and tirzepatide, you are not simply switching between two doses of the same thing

Study design and population The study enrolled 31 patients who had two things in common: obesity and chronic migraine

Though rare, serious side effects require prompt medical attention as they can affect organs such as the kidneys, pancreas, gallbladder, and eyes

For chronic weight management in adults with obesity, tirzepatide 15 mg delivered a mean 22.5% body weight reduction in the SURMOUNT-1 trial, compared to approximately 15% with semaglutide 2.4 mg in the STEP trials

The weight loss acceleration typically comes in the middle and higher dose ranges

Does the market keep expanding